Welcome to our dedicated page for Medtronic plc SEC filings (Ticker: MDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Medtronic plc's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Medtronic plc's regulatory disclosures and financial reporting.
MDT submitted a Form 144 notice related to the proposed sale of Common stock. The filing lists multiple prior issuances and acquisition events (ESPP purchases, restricted stock vesting, dividend reinvestment) with dates and per-event share counts included in the schedule.
Medtronic plc EVP & President, Neuroscience Thompson Kweli filed an initial Form 3 showing his current equity holdings in the company. He directly owns 30,017.737 ordinary shares and holds multiple stock option grants with varying exercise prices and expirations, plus performance share units that may convert into additional shares based on future vesting and performance conditions.
Medtronic plc provides a detailed overview of its global medical technology business, risks, and strategic priorities. The company operates across three main portfolios — Cardiovascular, Neuroscience, and Medical Surgical — offering devices from cardiac rhythm management and transcatheter valves to neuromodulation, surgical robotics, and acute care monitoring.
Medtronic highlights a major portfolio shift: its Diabetes Business is being separated into MiniMed Group, Inc., which completed an initial public offering in March 2026. The report also emphasizes heavy investment in R&D, expanded use of data, AI and automation, and a broad intellectual property base in an industry with intense competition and frequent litigation.
The company underscores human capital as a key asset, with over 95,000 employees, strong pay-equity metrics, and extensive learning programs. It also devotes substantial discussion to regulatory, reimbursement, data-privacy, trade, and environmental frameworks that shape how its products are developed, approved, manufactured, and paid for worldwide, including EU MDR, GDPR, and evolving AI regulation.
Medtronic plc executive Harry Skip Kiil reported selling Ordinary Shares in two open-market transactions. On June 8, 2026, he sold a total of 4,189 Medtronic Ordinary Shares in the open market at prices around $80.44–$80.45 per share. These are non-derivative transactions reported as direct ownership and represent routine insider sales rather than option exercises or gifts.
Medtronic plc executive Harry Skip Kiil reported a routine tax-withholding share disposition tied to equity compensation. On the transaction date, 6,817 Ordinary Shares were withheld at $83.32 per share to cover taxes upon settlement of performance-vesting restricted stock units that vested on April 24, 2026. After this non-market transaction, he directly holds 41,416 Medtronic Ordinary Shares.
Medtronic plc Chairman and CEO Geoffrey Martha reported a routine tax-related share disposition. On settlement of performance-vesting restricted stock units that vested on April 24, 2026, 41,936 ordinary shares were withheld to cover tax obligations at $83.32 per share. After this withholding, Martha directly holds 301,163 ordinary shares, and the filing does not show any open-market buying or selling.
Medtronic plc executive Michael Marinaro reported a routine tax-related share disposition. On April 24, 2026, performance-vesting restricted stock units vested, and on June 4, 2026, 7,471 Ordinary Shares were withheld at $83.32 per share to cover associated tax obligations. After this withholding, he directly holds 63,122 Ordinary Shares.
Medtronic plc senior vice president and Chief HR Officer Walter Matthew R. reported a routine tax-related share disposition. On June 4, 2026, 2,840 Ordinary Shares at $83.32 per share were withheld to cover taxes due on performance-vesting restricted stock units that vested on April 24, 2026. Following this withholding, he directly holds 38,689 Ordinary Shares.
Medtronic plc Chief Accounting Officer Denise L. Blomquist reported a routine tax-related share disposition. On April 24, 2026, performance-vesting restricted stock units vested, and 237 ordinary shares were withheld to cover taxes at a value of $83.32 per share. After this withholding, she directly holds 14,737 ordinary shares of Medtronic, indicating a small adjustment to her equity position tied to compensation rather than an open-market sale.